Fidelity Investments’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.05M | Buy |
338,939
+36,695
| +12% | +$579K | ﹤0.01% | 2490 |
|
|
2025
Q4 | $5.51M | Sell |
302,244
-430,418
| -59% | -$7.25M | ﹤0.01% | 2254 |
|
|
2025
Q3 | $10.7M | Sell |
732,662
-2,479,912
| -77% | -$42.5M | ﹤0.01% | 1970 |
|
|
2025
Q2 | $58.5M | Sell |
3,212,574
-152,421
| -5% | -$3.11M | ﹤0.01% | 1335 |
|
|
2025
Q1 | $66.8M | Buy |
3,364,995
+167,362
| +5% | +$2.89M | ﹤0.01% | 1254 |
|
|
2024
Q4 | $54.8M | Buy |
3,197,633
+1,252,802
| +64% | +$23.6M | ﹤0.01% | 1344 |
|
|
2024
Q3 | $38.9M | Buy |
1,944,831
+68,881
| +4% | +$1.07M | ﹤0.01% | 1476 |
|
|
2024
Q2 | $21M | Buy |
1,875,950
+1,871,824
| +45,367% | +$15.7M | ﹤0.01% | 1633 |
|
|
2024
Q1 | $27.2K | Buy |
4,126
+344
| +9% | +$1.88K | ﹤0.01% | 3881 |
|
|
2023
Q4 | $17.1K | Sell |
3,782
-455
| -11% | -$1.68K | ﹤0.01% | 4022 |
|
|
2023
Q3 | $15.2K | Buy |
4,237
+689
| +19% | +$2.65K | ﹤0.01% | 3939 |
|
|
2023
Q2 | $13.1K | Buy |
3,548
+528
| +17% | +$1.96K | ﹤0.01% | 4050 |
|
|
2023
Q1 | $10K | Sell |
3,020
-520
| -15% | -$1.8K | ﹤0.01% | 4132 |
|
|
2022
Q4 | $13.7K | Buy |
3,540
+100
| +3% | +$308 | ﹤0.01% | 3908 |
|
|
2022
Q3 | $8K | Buy |
3,440
+3,236
| +1,586% | +$7.76K | ﹤0.01% | 4144 |
|
|
2022
Q2 | $0 | Buy |
+204
| New | +$401 | ﹤0.01% | 4867 |
|
|
2021
Q3 | – | Sell |
-1
| Closed | – | – | 4269 |
|
|
2021
Q2 | $0 | Buy |
+1
| New | +$2 | ﹤0.01% | 4177 |
|
|
2018
Q2 | – | Sell |
-218,743
| Closed | -$1.01M | – | 2627 |
|
|
2018
Q1 | $1.01M | Sell |
218,743
-59,857
| -21% | -$238K | ﹤0.01% | 2438 |
|
|
2017
Q4 | $894K | Sell |
278,600
-94,100
| -25% | -$263K | ﹤0.01% | 2458 |
|
|
2017
Q3 | $1.15M | Sell |
372,700
-14,800
| -4% | -$49.3K | ﹤0.01% | 2402 |
|
|
2017
Q2 | $1.49M | Sell |
387,500
-12,200
| -3% | -$49K | ﹤0.01% | 2388 |
|
|
2017
Q1 | $1.95M | Sell |
399,700
-23,400
| -6% | -$115K | ﹤0.01% | 2360 |
|
|
2016
Q4 | $2.17M | Hold |
423,100
| – | – | ﹤0.01% | 2366 |
|
|
2016
Q3 | $3.07M | Hold |
423,100
| – | – | ﹤0.01% | 2288 |
|
|
2016
Q2 | $2.52M | Hold |
423,100
| – | – | ﹤0.01% | 2337 |
|
|
2016
Q1 | $3.42M | Hold |
423,100
| – | – | ﹤0.01% | 2257 |
|
|
2015
Q4 | $3.43M | Hold |
423,100
| – | – | ﹤0.01% | 2303 |
|
|
2015
Q3 | $3.54M | Hold |
423,100
| – | – | ﹤0.01% | 2275 |
|
|
2015
Q2 | $3.92M | Hold |
423,100
| – | – | ﹤0.01% | 2308 |
|
|
2015
Q1 | $4.15M | Hold |
423,100
| – | – | ﹤0.01% | 2277 |
|
|
2014
Q4 | $4.73M | Buy |
+423,100
| New | +$4.84M | ﹤0.01% | 2251 |
|
Other funds holding ADMA
VCM
VPM
N
Fidelity Investments's ADMA Position: Q1 2026 in Review
Fidelity Investments increased its ADMA Biologics (ADMA) stake by 12% in Q1 2026, buying an estimated $579K and bringing the position to 338,939 shares worth $3.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2490.
Fidelity Investments first reported a position in ADMA in Q4 2014 and has held it in 31 quarters since. The position peaked at $66.8M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.
- Fidelity Investments held 338,939 shares of ADMA Biologics worth $3.05M as of Q1 2026.
- Fidelity Investments bought 36,695 ADMA Biologics shares in Q1 2026, an estimated $579K.
- ADMA Biologics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2490 holding.
- Fidelity Investments first reported a position in ADMA Biologics in Q4 2014 and has held it in 31 quarters since.
- Fidelity Investments's ADMA Biologics position peaked at $66.8M in Q1 2025.
- 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.